Journal Article

<i>Escherichia coli</i>: Development of Carbapenem Resistance During Therapy

Tao Hong, Ellen Smith Moland, Baha Abdalhamid, Nancy D. Hanson, Jie Wang, Cindy Sloan, Diane Fabian, Awny Farajallah, Jerome Levine and Kenneth S. Thomson

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 40, issue 10, pages e84-e86
Published in print May 2005 | ISSN: 1058-4838
Published online May 2005 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/429822
Escherichia coli: Development of Carbapenem Resistance During Therapy

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

A 76-year-old woman had recurrent urosepsis due to extended-spectrum β-lactamase-positive Escherichia coli. Imipenem resistance was detected after long-term imipenem-meropenem therapy. The carbapenem-hydrolyzing enzyme gene was identified as blaKPC-3. To our knowledge, this is the first documented case in which carbapenem-resistant E. coli emerged during therapy with imipenem and meropenem, and the first identification of the carbapenem-hydrolyzing enzyme in E. coli isolates.

Journal Article.  1342 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.